Detalhe da pesquisa
1.
Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
BMC Cancer
; 24(1): 393, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38549044
2.
Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion.
BMC Pulm Med
; 24(1): 89, 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365707
3.
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18.
Transl Lung Cancer Res
; 13(4): 875-884, 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38736500
4.
Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors.
Transl Lung Cancer Res
; 12(9): 1935-1948, 2023 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37854161
5.
[Advances in the Study of Tissue-resident Memory T Cells in Lung Cancer].
Zhongguo Fei Ai Za Zhi
; 25(12): 862-869, 2022 Dec 20.
Artigo
em Zh
| MEDLINE | ID: mdl-36617472
6.
Impact of non-canonical ALK fusion on the efficacy of targeted therapy in non-small cell lung cancer.
Chin Med J (Engl)
; 2023 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38032041